Results 31 to 40 of about 4,626,170 (385)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Frontiers in Oncology, 2022
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated.
Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu   +5 more
doaj   +1 more source

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.

JAMA Oncology, 2021
Importance Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established.
E. Fokas, A. Schlenska-Lange, B. Polat, G. Klautke, G. Grabenbauer, R. Fietkau, T. Kuhnt, L. Staib, T. Brunner, A. Grosu, S. Kirste, L. Jacobasch, M. Allgäuer, M. Flentje, Christoph‐Thomas Germer, R. Grützmann, G. Hildebrandt, M. Schwarzbach, W. Bechstein, H. Sülberg, T. Friede, J. Gaedcke, M. Ghadimi, R. Hofheinz, C. Rödel   +24 more
semanticscholar   +1 more source

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.

The Journal of the National Comprehensive Cancer Network, 2022
The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is ...
Laura M. Spring, Yael Bar, S. Isakoff
semanticscholar   +1 more source

Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis.

The Oncologist, 2021
OBJECTIVE & BACKGROUND Total neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery.
Shuang Liu, Ting Jiang, Lin Xiao, Shanfei Yang, Qing Liu, Yuan-hong Gao, Gong Chen, W. Xiao   +7 more
semanticscholar   +1 more source

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

Journal of Hematology & Oncology, 2022
Background Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited.
Z. Zhou, Z. Ding, J. Yuan, S. Shen, H. Jian, Q. Tan, Yu-Chung Yang, Z. Chen, Q. Luo, X. Cheng, Y. Yu, X. Niu, L. Qian, X. Chen, L. Gu, R. Liu, S. Ma, J. Huang, T. Chen, Z. Li, W. Ji, L. Song, L. Shen, L. Jiang, Z. Yu, C. Zhang, Z. Tai, C. Wang, R. Chen, S. Lu   +29 more
semanticscholar   +1 more source

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +1 more source

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.

JAMA Oncology, 2021
Importance Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease.
O. Rahma, G. Yothers, T. Hong, M. Russell, Y. You, W. Parker, S. Jacobs, L. Colangelo, P. C. Lucas, M. Gollub, W. Hall, L. Kachnic, Namrata Vijayvergia, M. O'Rourke, B. Faller, R. Valicenti, T. Schefter, K. Moxley, R. Kainthla, P. Stella, E. Sigurdson, N. Wolmark, T. George   +22 more
semanticscholar   +1 more source

Management of inoperable endometrial cancer [PDF]

Obstetrics & Gynecology Science, 2022
Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types of treatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatment before surgery. Radiation therapy
Supakorn Pitakkarnkul, Saranya Chanpanitkitchot, Siriwan Tangjitgamol   +2 more
doaj   +1 more source